Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen

Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease

Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly

The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study